

Patient Details

Patient Name: DOB: Phone:

Address:

Medicare: Clinical Trial / ID no.:

PET Indications

- | | |
|---|---|
| Lung – Solitary Pulmonary Nodule [61523] | Metastatic SCC w/ Cervical LNs– Unknown Primary [61610] |
| Lung – NSCLC [61529] | Lymphoma – Initial Staging [61620] |
| Breast Cancer – Locally Advanced [61524] | Lymphoma – Therapy Response [61622] |
| Breast Cancer – Suspected Metastasis/Recurrence [61525] | Lymphoma – Restaging Recurrence [61628] |
| Brain - Tumour – Recurrence [61538] | Lymphoma – Post 2nd Line Chemotherapy [61632] |
| Brain - Epilepsy [61559] | Sarcoma Bone/Soft Tissue – Staging [61640] |
| Brain - Alzheimer's Disease [61560] | Sarcoma – Residual/Recurrence [61646] |
| Oesophageal/GEJ Carcinoma [61577] | Rare Cancer – Initial Staging [61612] |
| Colorectal [61541] | Rare Cancer – Residual/Recurrence [61614] |
| Melanoma [61553] | Prostate PSMA – Initial Staging [61563] |
| Ovarian – Recurrence [61565] | Prostate PSMA – Restaging/Recurrence [61564] |
| Uterine Cervix – Staging [61571] | Prostate PSMA – Assessment for ¹⁷⁷ Lu-PSMA Therapy [61528] |
| Uterine Cervix – Pelvic Recurrence [61575] | Neuroendocrine Tumour – ⁶⁸ Ga-Dotatate [61647] |
| Head/Neck – Staging [61598] | Other (non-Medicare rebatable) PET/CT |
| Head/Neck – Residual [61604] | |

MBS ineligible items will incur an out of pocket fee. MBS items must be specialist referred.

Diagnostic CT Examination

PET/CT examinations include a low-dose CT for attenuation correction and anatomical localisation only. Diagnostic contrast-enhanced CT examinations will be performed only upon request.

CT Chest/Abdo/Pelvis (CAP) CT Head CT Neck CT Chest CT Abdomen/Pelvis CT Pulmonary Angiogram

CT 3-Phase - specify:

CT Other - specify:

Clinical Notes

Contrast Allergy Renal Impairment Diabetic Staging Restaging Surveillance

Previous Imaging: No Yes, at

Referring Practitioner

Referrer Name: Referrer Phone Number:

Practice Address: Healthlink ID:

Report Distribution: Electronic Fax

Send Report Copy to: Signature:

Date of Referral:

Lung

Lung – Solitary Pulmonary Nodule [61523]

Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.

Lung – NSCLC [61529]

Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.

Brain

Brain - Tumour – Recurrence [61538]

FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.

Brain - Epilepsy [61559]

FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.

Brain - Alzheimer's Disease [61560]

FDG PET brain for diagnosis of Alzheimer's disease if clinical evaluation (by or in consultation with a specialist) is equivocal. *Not repeatable within 12 months and not more than 3 per lifetime.*

Gastrointestinal

Colorectal [61541]

Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.

Oesophageal/GEJ Carcinoma [61577]

Whole body FDG PET study, performed for the staging of proven oesophageal or GOJ carcinoma, in patients considered suitable for active therapy.

Gynaecology

Ovarian – Recurrence [61565]

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.

Uterine Cervix – Staging [61571]

Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.

Uterine Cervix – Pelvic Recurrence [61575]

Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.

Head & Neck

Head/Neck – Staging [61598]

Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head & neck cancer.

Head/Neck – Residual [61604]

Whole body FDG PET study performed for the evaluation of patients with suspected residual head & neck cancer after definitive treatment, and who are suitable for active therapy.

Melanoma

Melanoma [61553]

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.

SCC

Metastatic SCC w/ Cervical LNs– Unknown Primary [61610]

Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.

Lymphoma

Lymphoma – Initial Staging [61620]

Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma.

Lymphoma – Therapy Response [61622]

Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin or non-Hodgkin lymphoma.

Lymphoma – Restaging Recurrence [61628]

Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin or non-Hodgkin lymphoma.

Lymphoma – Post 2nd Line Chemotherapy [61632]

Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered for Hodgkin or non-Hodgkin lymphoma.

Sarcoma

Sarcoma Bone/Soft Tissue – Staging [61640]

Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.

Sarcoma – Residual/Recurrence [61646]

Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.

Breast

Breast Cancer – Locally Advanced [61524]

Whole body FDG PET study, performed for the staging of locally advanced (stage III) breast cancer, for a patient who is considered suitable for active therapy.

Breast Cancer – Suspected Metastasis/Recurrence [61525]

Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy.

Prostate

Prostate PSMA – Initial Staging [61563]

Whole Body PSMA PET for initial staging of intermediate to high risk prostate adenocarcinoma for previously untreated patient, considered for locoregional therapy with curative intent. *Once per lifetime.*

Prostate PSMA – Restaging/Recurrence [61564]

Whole body PSMA PET for restaging of recurrent prostate adenocarcinoma of patient who has undergone prior locoregional therapy and considered suitable for further locoregional therapy to determine appropriate further therapy. *Twice per lifetime.*

Prostate PSMA – Assessment for ¹⁷⁷Lu-PSMA Therapy [61528]

Whole body PSMA PET performed for the assessment of suitability for Lutetium - 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer.

Neuroendocrine

Neuroendocrine Tumour – ⁶⁸Ga-Dotatate [61647]

Whole body ⁶⁸Ga DOTA peptide PET study, if: (a) a gastro entero pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or (b) both: (i) a surgically amenable gastro entero pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and (ii) the study is for excluding additional disease sites.


Rare/Uncommon Cancer Staging

Rare Cancer – Initial Staging [61612]

Whole body FDG PET study for the initial staging of cancer, for a patient who is considered suitable for active therapy, if:
(a) the cancer is a typically FDG-avid cancer; and
(b) there is at least 10% likelihood that a PET study result will inform a significant change in management for the patient.
Limit once per cancer diagnosis.

Rare Cancer – Residual/Recurrence [61614]

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent cancer in a patient who is undergoing, or is suitable for, active therapy, if the cancer is a typically FGD-avid cancer.



Icon Cancer Centre Hollywood is located within the Hollywood Medical Centre. When arriving via Monash Ave, enter through Gate 5.



Book an Appointment

To book an appointment call: **+618 6326 1130**

iconcancercentre.com.au

Your doctor has recommended you attend Icon Cancer Centre. You may choose another provider but please discuss this with your doctor first.